Assay Guidance Workshop Agenda — March 26-27, 2018

March 26, 2018 — 7:30 a.m. - 5:00 p.m. ET

William F. Bolger Center, 9600 Newbridge Drive, Potomac, MD 20854

7:30 a.m.: Registration

8:00 a.m.: Robust Assays Define Success in Preclinical Research 
Nathan P. Coussens, Ph.D., NCATS, NIH

8:15 a.m.: Target Validation in Physiologically Relevant Drug Discovery Models
Madhu Lal-Nag, Ph.D., NCATS, NIH

9:00 a.m.: Concepts in the Development and Validation of Robust Cell-Based and Biochemical Assays
Timothy L. Foley, Ph.D., Pfizer Inc.

9:45 a.m.: Beverage Break

10:00 a.m.:Treating Cells as Reagents to Design Reproducible Screening Assays
Terry Riss, Ph.D., Promega Corporation

10:45 a.m.:  Assay Development for High-Content Screening
O. Joseph Trask, Jr., PerkinElmer, Inc.

11:30 a.m.: Remarks from the Director of NCATS
Christopher P. Austin, M.D., NCATS, NIH

11:45 a.m.:  Lunch

1:00 p.m.: Introduction to Mass Spectrometry for Drug Screening and Lead Optimization
Kenneth D. Roth, Ph.D., Eli Lilly and Company

1:45 p.m.: Assay Interference by Chemical Reactivity
Jayme L. Dahlin, M.D., Ph.D., Brigham and Women’s Hospital

2:30 p.m.: Lead Selection and Optimization by Medicinal Chemistry
Samarjit Patnaik, Ph.D., NCATS, NIH

3:15 p.m.: Beverage Break

3:30 p.m.: In Vitro Toxicological Testing Using a qHTS Platform
Menghang Xia, Ph.D., NCATS, NIH

4:15 p.m.: In Vitro Assessments of ADME Properties of Lead Compounds
Xin Xu, Ph.D., NCATS, NIH

5:00 p.m.: Adjourn

March 27, 2018 — 7:30 a.m. - 5:00 p.m. ET

NCATS, 9800 Medical Center Drive, Rockville, Maryland 20850

7:30 a.m.: Registration

8:00 a.m.: Statistical Design of Experiments for Assay Development
Steven D. Kahl, Eli Lilly and Company

8:45 a.m.: The Application of Pharos for Target Evaluation and Drug Discovery
Rajarshi Guha, Ph.D., NCATS, NIH

9:30 a.m.: Basic Assay Statistics, Data Analysis and Rules of Thumb
Thomas D.Y. Chung, Ph.D., Sanford Burnham Prebys Medical Discovery Institute

10:15 a.m.: Beverage Break

10:30 a.m.: Reproducibility and Differentiability of Compound Potency Results from Screening Assays in Drug Discovery
Viswanath Devanarayan, Ph.D., Charles River Laboratories

11:15 a.m.: Assay Operations: Keeping Your Assays Robust and Reproducible
Jeffrey R. Weidner, Ph.D., QualSci Consulting, LLC

12:00 p.m.: Thoughts and Perspective
Anton Simeonov Ph.D., NCATS, NIH

12:15 p.m.: Lunch 

1:45 p.m.: Hands-On Data Analysis Sessions

5:00 p.m.: Adjourn